Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTBK1 | Q5TCY1 | 4/20 | 0.41 |
| ▸ | CHUK | O15111 | 6/20 | 0.41 |
| ▸ | LYN | P07948 | 1/20 | 0.39 |
| ▸ | SRC | P12931 | 1/20 | 0.39 |
| ▸ | BTK | Q06187 | 1/20 | 0.39 |
| ▸ | GRM5 | P41594 | 1/20 | 0.39 |
| ▸ | CCR1 | P32246 | 1/20 | 0.39 |
| ▸ | CCR5 | P51681 | 1/20 | 0.39 |
| ▸ | CCR8 | P51685 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | NOS3 | P29474 | 1/20 | 0.36 |
| ▸ | NOS2 | P35228 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18034675 | 0.80 | TTBK1 (0.43) | TTBK1CHUK | |
| SCHEMBL739722 | 0.80 | GRM5 (0.47) | TTBK1CHUKGRM5KMT2AATM | |
| SCHEMBL8972795 | 0.80 | TTBK1 (0.38) | TTBK1CHUKKMT2A | |
| SCHEMBL25486882 | 0.80 | TTBK1 (0.38) | TTBK1CHUKKMT2AATM | |
| SCHEMBL4520127 | 0.80 | TTBK1 (0.38) | TTBK1CHUKKMT2AATM | |
| SCHEMBL5545972 | 0.76 | TTBK1 (0.43) | TTBK1CHUKCCR1CCR5CCR8 | |
| SCHEMBL16673635 | 0.76 | P4HA1 (0.46) | GRM5 | |
| SCHEMBL24960004 | 0.76 | GRM5 (0.36) | CHUKGRM5CCR1CCR5CCR8 | |
| SCHEMBL4521359 | 0.75 | MCHR1 (0.42) | CHUK | |
| SCHEMBL12295342 | 0.74 | CCR1 (0.46) | SRCBTKGRM5CCR1CCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210139494-A1 | HETEROCYCLIC RIP1 INHIBITORY COMPOUNDS | RIGEL PHARMACEUTICALS, INC. (US) | 2021-05-13 | — | — | US | disclosed |
| US-20200276180-A1 | POLYCYCLIC COMPOUND ACTING AS IDO INHIBITOR AND/OR IDO-HDAC DUAL INHIBITOR | HANGZHOU INNOGATE PHARMA CO., LTD (CN) | 2020-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200276180-A1 | POLYCYCLIC COMPOUND ACTING AS IDO INHIBITOR AND/OR IDO-HDAC DUAL INHIBITOR | IDO1, HDAC1, HDAC2 | TTBK1 2215/4885CHUK 109/4885LYN 3245/4885 |
| US-20210139494-A1 | HETEROCYCLIC RIP1 INHIBITORY COMPOUNDS | RIPK1, RIPK2, RIPK3 | TTBK1 867/4885CHUK 130/4885LYN 1661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.